Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Biogen (BIIB) falls as earnings, revenue misses consensus

February 13, 2024 7:24 AM EST

Biogen (NASDAQ: BIIB) shares are down more than 5% premarket Tuesday after the company reported earnings for its latest quarter, missing the consensus profit and revenue estimate.

The biotechnology firm reported fourth-quarter earnings of $2.95 per share, $0.23 worse than the analyst estimate of $3.18.... More